Cellectis (NASDAQ:CLLS - Get Free Report) was upgraded by equities researchers at StockNews.com from a "hold" rating to a "buy" rating in a research note issued on Friday.
Cellectis Trading Up 3.5 %
Cellectis stock traded up $0.06 during mid-day trading on Friday, hitting $1.65. The company's stock had a trading volume of 44,690 shares, compared to its average volume of 145,275. The stock's fifty day moving average is $1.33 and its two-hundred day moving average is $1.61. Cellectis has a 1 year low of $1.10 and a 1 year high of $3.38. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $91.44 million, a PE ratio of -1.27 and a beta of 3.22.
Cellectis (NASDAQ:CLLS - Get Free Report) last issued its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by ($0.22). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The firm had revenue of $33.22 million for the quarter, compared to analyst estimates of $5.90 million. On average, analysts anticipate that Cellectis will post -0.46 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. B Group Inc. bought a new position in shares of Cellectis in the 4th quarter valued at approximately $5,547,000. Millennium Management LLC bought a new stake in shares of Cellectis in the 4th quarter valued at about $962,000. Finally, Wells Fargo & Company MN raised its holdings in Cellectis by 103.4% during the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock worth $44,000 after buying an additional 12,500 shares during the period. 63.90% of the stock is owned by institutional investors and hedge funds.
Cellectis Company Profile
(
Get Free Report)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Featured Articles
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
